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‘Lipodystrophy syndrome’ in the setting of HIV infection
has come to encompass a collection of morphological
and metabolic abnormalities linked with the use of
antiretroviral therapy and other risk factors. We review
the clinical literature on this subject as it has evolved
historically, taking pertinent methodological issues into
account.
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The use of the term ‘lipodystrophy’ originates in two
reports, one published in late 1997 and the other in early
1998, describing wasting of subcutaneous fat in the face
and limbs of HIV-infected patients treated with the
protease inhibitor (PI) indinavir, reminiscent of rare
congenital and acquired lipodystrophy syndromes [1,2].
From late 1997 onwards, others described benign
symmetric lipomatoses, localized lipomas, ‘buffalo
humps’, intra-abdominal fat accumulation and breast
enlargement in HIV-infected men and women on various
antiretroviral combinations, predominantly (but not
exclusively) including PIs [3–20]. Altered lipoproteins,
mimicking the ‘atherogenic’ profile seen in dyslipidaemic
diabetics; elevated (fasting) serum triglyceride, LDL- and
VLDL-cholesterol, apolipoprotein B, E and lipopro-
tein(a) and reduced HDL-cholesterol were also
documented in PI-treated patients and shown to precede
body habitus changes in some cases [21–32]. Insulin
resistance and diabetes mellitus developed de novo or
worsened in patients (with and without morphological
change), co-incident with starting a PI [2,21,26,32–38].
The fat wasting and the hypertriglyceridaemia were
distinguished from that previously described in AIDS
by the fact that they typically occurred in those
successfully treated with highly active antiretroviral
therapy (HAART), even in acute HIV infection and as
post-exposure prophylaxis [39–41]. Patients experi-
enced psychological morbidity and increased barriers
to good adherence to therapy because of these prob-
lems [42,43]. In addition, the spectre of accelerated
atherosclerosis was raised by a flurry of case reports of
macrovascular (mainly coronary) disease in young
dyslipidaemic patients on HAART [44–53].
The first systematic study of these phenomena, in a
large Australian cohort, found that subcutaneous fat
wasting in the face, limbs, buttocks and upper trunk
(termed ‘peripheral lipodystrophy’) was associated
with abdominal visceral obesity, dyslipidaemia and
insulin resistance in HIV-infected patients [54]. The
vast majority of affected cases were on PI-containing
HAART. The facts that morphological and metabolic
changes appeared to aggregate at a population level,
their phenotypic similarity to ‘Syndrome X’ and the
plausibility of PIs as a unifying cause, all helped drive
the view that these changes formed a new single
‘lipodystrophy syndrome’ [54–56] (Figure 1).
Over the last 2 years, evidence has emerged that body
habitus changes, and lipid and glycaemic parameters
may behave as independent or partially independent
processes [21,57,58]. Not one, but three patterns of
body habitus change are discernible within individuals,
fat wasting alone (or ‘pure lipoatrophy’), fat accumula-
tion alone or a combination of both [58–60].
Furthermore, factors other than PIs – such as nucleoside
analogue reverse transcriptase inhibitors (NRTIs), age,
gender and race – may independently influence the risk
of developing some of these changes [59–72].
Differential effects of antiretroviral agents within the PI
and NRTI classes are also possible
[54,59,60,62,63,70–72]. Rather than a stereotypic
syndrome with a single cause, the ‘lipodystrophy
syndrome’ is increasingly studied as a set of distinct clin-
ical abnormalities – fat loss, fat gain, dyslipidaemia and
insulin resistance – that may complicate antiretroviral
therapy to variable degrees in different individuals. The
extent to which these abnormalities are inter-related is
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Historynot clear, and may not ever be so, until their exact
aetiopathogenesis is understood. However, attempts to
characterize the general phenomenology enough to
develop standardized case-definition(s) is important in
the meantime.
For researchers, designing lipodystrophy studies (of
observational cohort data, randomized clinical trials or
pathogenesis studies) and for clinicians that must criti-
cally evaluate these studies, several methodological
issues have already emerged. Most importantly, the
‘lipodystrophy syndrome’ cannot be analysed as a single
entity at this time. Initially, its components should be
analysed individually, though they may have partially
overlapping risk factors and intersecting pathogenic
pathways. Secondly, study method should be concor-
dant with the dynamic nature of these outcomes.
Methodological issues
Cross-sectional versus longitudinal study design
To date, most studies have used cross-sectional design to
analyse cumulative phenomena. Subcutaneous fat
wasting, in particular, is a progressive process that
increases in severity over time. At some point, this
continuous change becomes evident to both patient and
physician and ‘clinically apparent’ fat wasting can then
be said to be present. The assignment of this outcome as
being ‘present’ or ‘not present’ at the arbitrary time of a
cross-sectional analysis is entirely subjective, and is
therefore only an approximation of the true division of
affected versus non-affected cases in a population. For
example, patients who do not have clinically apparent
fat wasting may either be truly unaffected or have subtle
or less severe change. Fat loss may well be evident on
more sensitive, objective measurement of fat mass over
time in these patients. On the other hand, patients with
clinically apparent fat wasting may have had the
problem for a long or a short period of time.
The various forms of fat accumulation, dyslipi-
daemia and insulin resistance are also acquired changes
from a previous baseline. Pre-existing genetically deter-
mined risk, as well as HIV infection itself can influence
the ‘baseline’ in any patient before starting antiretro-
viral therapy. Because of the sequential use of various
antiretroviral drugs and drug classes historically, cross-
sectional studies are also inherently likely to find
associations between cumulative outcomes and drugs
in current use, even when drugs in past use are the true
culprits. Longitudinal studies in which deviations from
baseline are recorded in real-time offers the best way to
characterize treatment-associated changes.
Objective body composition measurement
The need for objective measurements has been under-
scored by the results of the PIILR study, in which serial
whole-body dual-energy X-ray absorptiometry
(DEXA) scans showed that replacement of PI with one
of several non-PI therapies caused worsening of subcu-
M John et al.
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Figure 1. Time-line of developments in antiretroviral treatment and ‘lipodystrophy syndrome(s)’
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reported fat gain [73].
DEXA has dominated as the test of choice in studies
of fat wasting, as it is quick to perform and is precise
and accurate for small changes in total body and appen-
dicular fat mass. The infrastructure for its use is usually
established in centres that routinely offer bone density
monitoring. The abdominal subcutaneous and visceral
fat compartments may change in opposing directions in
some patients, so single-cut CT scans at L4 are prefer-
able to DEXA for analysing abdominal fat [14,68]. ‘Fat
redistribution’ is a term favoured by some, but simulta-
neous fat loss/fat gain is not present in all patients, so it
may be unwise to use appendicular to central fat ratios
derived from DEXA scans as a global measure of any
possible morphological change. For example, patients
with subcutaneous fat wasting but no visceral fat accu-
mulation may have a low appendicular to central fat
ratio, comparable to those with well preserved subcuta-
neous fat. Whole-body magnetic resonance imaging
(MRI) is highly precise and accurate [74], but is not
widely available and may be prohibitively expensive.
Cheaper techniques such as anthropometry, bioelec-
tric impedance testing (BIA) and ultrasonography are
attractive for clinical practice, but all may lack both
precision and accuracy unless conducted under highly
standardized conditions. Ultrasonography has only
been evaluated against clinically assigned ‘lipodys-
trophy’ cases, not against validated techniques such as
DEXA or MRI [75]. Both DEXA and MRI are less
operator-dependent than ultrasound and BIA, but still
require standardization of calibration when compared
between machines and centres. Whatever the tech-
nology of choice, tests carried out serially in
treatment-naive patients acting as their own controls,
reduce the difficulties of inter-machine variability.
Statistical methods
Most studies have needed to use logistic regression
models to do multivariate analysis because of their
cross-sectional design, although this method is inher-
ently not suited to time-dependent outcomes.
Longitudinal studies, ideally starting in treatment-naive
patients prior to therapy, naturally lend themselves to
time-to-event statistical analyses such as Cox propor-
tional hazards models or Kaplan–Meier estimates. These
methods give a more accurate relative risk associated
with antiretroviral drug exposure in particular, because
the outcome is recorded in the context of the specific
drug taken at the time the outcome first develops, as
opposed to the drug most recently taken.
Stavudine was introduced to clinical practice some
years after zidovudine, and not long before the first PI.
Individual PIs followed in comparatively quick succes-
sion. Hence, the whole PI class and stavudine were the
predominant ‘current’ therapies in many early study
populations and may have been partial surrogate
markers for each other, as well as for prior prolonged
NRTI therapy (Figure 1). However, studies that simply
compared current PI-treated with PI-naive patients
(without matching concurrent/past therapies), were
designed  a priori to implicate PIs. Any independent
contribution of current or past NRTIs to any outcome of
interest could never have been determined. There is now
evidence that duration of NRTI therapy is independently
associated with subcutaneous fat wasting in PI-treated
and PI-naive patients, and hence this may confound
analysis of PI effects and comparisons within the NRTI
class in cross-sectional studies [59,60,62,63,70–72].
Case definition
If the ideal methodological approach to a cumulative
process could always be followed (objective body
composition measurement with known precision limits,
repeated at sufficient frequency from a known baseline,
before any antiretroviral therapy, adjusted for diet and
exercise) an ‘ideal’ case definition could also be based on
such approaches. For example, case definition criteria
for fat wasting might be of the form ‘a >x% loss in
percentage leg fat on DEXA scan from pre-treatment
baseline without significant loss in lean body mass or
change to diet or exercise over 6 months’. In real clinical
practice however, the data to develop such a ‘longitu-
dinal’ case definition are rarely available. Patients with
unknown pre-treatment baselines for body composition,
lipid and glycaemic parameters may present at any stage
of their treatment history. Hence, a practical case defin-
ition, which can be applied at a single assessment will be
helpful to researchers and clinicians that only have
cross-sectional data. A multi-centre case definition study
aiming to generate a cross-sectional case definition for
morphological changes with discriminative specificity
against disease controls such as ‘HIV wasting syndrome’
and obesity (and similarly for metabolic changes) is now
underway.
Risk factors
The variability in case ascertainment, end-points, statis-
tical methods and adjustment for bias may explain the
variability in prevalence figures and variability in the
magnitude of risk associated with some factors in many
cross-sectional, observational cohort studies. However,
certain risk factors have been consistently identified across
studies, and their associations with lipodystrophy-related
outcomes has not been abrogated where adjustment to
minimize confounding factors has been attempted [63].
More recent retrospectively designed lipodystrophy
substudies within prospective randomized clinical trials
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of a contributory role for these factors discussed below.
Protease inhibitors
The odds of having fat wasting increases with the dura-
tion of PI treatment [56,62,63]. Time to onset of
clinically apparent fat wasting is markedly accelerated
when PIs and NRTIs are combined compared with
NRTIs alone [63]. PI use also increases the probability
of intra-abdominal fat accumulation, dyslipidaemia and
insulin resistance in HIV-infected patients [21,54,56].
Short-term ritonavir use leads to dyslipidaemia in the
absence of body composition changes in healthy volun-
teers [76], and elevated triglyceride levels have also been
observed in HIV-seronegative individuals receiving
short-term PIs (predominantly indinavir) for post-expo-
sure prophylaxis [77]. All PIs licensed in 1996/1997
have been implicated, though ritonavir is more likely to
cause malignant hypertriglyceridaemia compared with
other PIs [21,32]. Amprenavir may be relatively benign
[78].
Table 1 summarizes the results of reversibility studies
that may give indirect evidence of the contribution of PIs
to lipodystrophy syndrome(s). Replacement of PI with
abacavir or the NNRTI nevirapine leads to decreased
serum triglyceride levels and LDL cholesterol levels after
6–12 months [73,79–84]. Insulin resistance measured by
rigorous intravenous insulin tolerance testing (ITT) also
improves after PI to abacavir switch [82,84]. A PI to
efavirenz switch appears to have less impact on meta-
bolic abnormalities and can cause a rise in cholesterol
levels, though this may be predominantly HDL-choles-
terol [85–89]. Improved insulin sensitivity has not been
shown with efavirenz introduction after 1 year of
follow-up [90]. Objective improvement in fat wasting up
to 12 months has not been demonstrated in any PI
switch study to date where concurrent NRTI treatment
has continued or been intensified [73,79–89].
M John et al.
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Table 1. Summary of switching studies
Study Follow-up Body Insulin 
author [ref] Switch Randomized n weeks habitus TGs Cholesterol resistance
Martinez et al. PI to NVP No 23 32 WHR 57% 22% 45%
[79]
Riuz et al. PI to NVP Yes 60 36 NS (DEXA) 23% 11% NS
[80]
Tebas et al. PI to NVP No 40 30 NS (DEXA) 44% No change in LDL. ITT normalized
[81] Rise in HDL  in three patients
cholesterol with high BSL
Goebal et al. PI to ABC Yes 211 40 -
[82]
CNA30017
Rozenbaum PI to ABC Yes 32 12 NS (skin NS NS NS
et al. [83] folds WHR)
CNA30017
Carr et al. PI to ABC Yes 80 24 Worsening of NS
PIILR study NVP s.c. fat loss
[73] HU (DEXA)
ADV
Moyle et al. PI to EFV No 11 12 – –
[85]
Gharakhanian PI to EFV No 33 48 NS NS NS NS
et al. [86] (skin-fold)
Bonnet et al. PI to EFV No 43 24 NS NS NS NS
[87] (DEXA)
Martinez et al. PI to EFV No 20 24 WHR 31% NS 28%
[88]
Viciana et al. PI to EFV No 39 24 NS –
[89] (WHR)
Saint Marc et al. d4T to ZDV or ABC No 59 52 Leg s.c. fat 29% NS NS
[94] 36%
(CT)
Polo et al. d4T/ddI to ZDV/3TC No 10 24 – – –
[95]
NS, no statistically significant change reported; WHR, waist hip ratio; PI, protease inhibitor; ABC. abacavir; ADV, adefovir; d4T, stavudine; ddI, didanosine; EFV,
efavirenz; NVP, nevirapine; ZDV, zidovudine; 3TC, lamivudine; HU, hydroxyurea; ITT, insulin tolerance test; BSL, blood sugar level; s.c., subcutaneous.Nucleoside analogue reverse transcriptase inhibitors
NRTIs as a class also increases the risk of fat wasting
[59,60,62–64,70–72], and NRTI therapy alone, in the
absence of PI use, is a sufficient condition for these
changes to arise [59,61–63,71). As with PI use, risk is
duration-dependent [63]. Within the class of NRTIs,
stavudine use provides a greater risk than zidovudine use
in non-randomized studies [59,60,62,63,71,72]. The
excess risk of stavudine has been estimated at 1.9 for the
first 18 months of therapy, after adjustment for the
potential biases against stavudine in observational data,
including older age and longer prior NRTI therapy in
some stavudine users [63]. A randomized clinical trial in
treatment-naive patients, comparing zidovudine/lamivu-
dine with stavudine/didanosine, found that fat loss and
fat gain occurred in both groups, but the
stavudine/didanosine arm showed consistently higher
prevalence up to 30 months of follow-up [91]. This
concurs with pooled cross-sectional analysis of patients
enrolled in a lipodystrophy substudy of two randomized
clinical trials comparing stavudine/didanosine, stavu-
dine/lamivudine or zidovudine/lamivudine with either
indinavir (Ozcombo I) or nevirapine (Ozcombo II) as a
first antiretroviral regimen. Fat wasting by physician
assessment and DEXA scan was associated with a stavu-
dine-containing regimen, with greatest prevalence in the
stavudine/didanosine groups [92]. A more recent
randomized trial comparing stavudine/lamivudine/indi-
navir to zidovudine/lamivudine/indinavir regimens in 96
stavudine/PI-naive patients has also found a higher
prevalence of peripheral fat wasting in the stavudine
group at 30 months [93]. Two non-randomized
reversibility trials show a (slow) increase in fat mass and
reductions in triglyceride 12 months after switch from
stavudine to zidovudine or abacavir [94,95] (Table 1).
Comparisons between competing antiretroviral agents
such as stavudine and zidovudine or, to a lesser extent
lamivudine and didanosine, can be made within the
NRTI class. However, it is inherently problematic to
assess the risk of zidovudine (or stavudine) relative to
lamivudine (or didanosine), as they are so often used
together. Lamivudine has been associated with abdom-
inal obesity and buffalo humps in one study [62] but
others have detected no associations. As abacavir has
tended to be used in place of PIs or NNRTIs in triple
NRTI HAART regimens, its own effects relative to other
NRTIs are yet to be determined.
It has not been clear from observational data
whether NRTIs are both sufficient and necessary for
development of lipodystrophy, as PI treatment without
past or current NRTIs is rare in clinical practice.
However, two randomized studies of dual PI therapy
(ritonavir/saquinavir) in the absence of NRTI use have
shown a low risk of subjective body composition
changes (~6–8%) over 2–4 years of follow-up [96,97].
Intensification of therapy with stavudine was associ-
ated with an increased incidence of lipodystrophy
(predominantly fat wasting [97]), to ~25% in both
studies. This would suggest that risk of fat wasting is
dominated by inclusion of stavudine into a PI (riton-
avir/saquinavir)-alone regimen.
Visceral obesity has been anecdotally noted in PI-
naive individuals [74], but overall the link between
NRTIs and intra-abdominal fat accumulation is weak
[60,71,93]. With respect to metabolic abnormalities,
mild-to-moderate hypertriglyceridaemia (and hyperlac-
tataemia) has been demonstrated in PI-naive patients,
where it has been associated with duration of stavudine
[99] and shown to regress after replacement of stavudine
[94]. However, stavudine did not have a significant
effect on triglyceride and total cholesterol levels
compared with ritonavir/saquinavir in the Prometheus
study [99]. In general, dyslipidaemia and insulin resis-
tance appears predominantly PI-, not NRTI-related.
Host factors
Older age increases risk of subcutaneous fat wasting
[60,63,100]. Gender may have an influence on the
lipodystrophy phenotype. Increased truncal adiposity,
rather than subcutaneous fat wasting, appears to be a
dominant manifestation in women [68,100–104], an
observation confirmed in a MRI study of body compo-
sition [103]. In general, the visceral fat depot makes only
a small contribution to total adipose stores in women
(~6%) compared with men (~20%) [105], a factor
which is thought to decrease the risk of vascular disease
in women [106]. In contrast, women with lipodystrophy
may develop a more ‘android’ body habitus with
waist:hip ratios closely approximating those of affected
men [101]. This is associated with hyperinsulinaemia,
hyperandrogenaemia (increased free testosterone and
increased LH:FSH ratio) and hyperlipidaemia [107],
which appears to be determined predominantly by
visceral fat mass rather than with PI therapy per se
[101,102,107]. The striking lack of difference in insulin,
glucose and lipid levels between age-matched men and
women on antiretroviral therapy in a recent study high-
lights the ‘android’ nature of both metabolic and body
composition changes in women [101].
Independent studies in diverse populations have
found that race influences the risk of body habitus
changes. White Caucasian race increased relative risk of
subcutaneous fat wasting by 3.9 times in an Australian
cohort [63]. White race was also associated with
increased prevalence of fat wasting in a multicentre US
cohort study [104] and, conversely, African-American
origin decreased risk of fat wasting in another US cohort
[69]. Study of a Nigerian cohort suggests that the preva-
lence of truncal obesity (~60%) is greater than that of fat
wasting (~30%) in this group [108]. Among Oriental
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body composition changes on DEXA scan among 45
individuals receiving PI-containing HAART, despite
significant increases in triglyceride and insulin levels, and
lower HDL-cholesterol, compared to controls [109]. A
study of a mainly Chinese Singaporean cohort found
that PIs were significantly associated with fat accumula-
tion and mixed accumulation and atrophy, while
prevalence of isolated fat wasting was not increased in
treated HIV-infected patients [110]. In contrast, a preva-
lence study in Japan has indicated a profile very similar
to that seen in Caucasian populations [111].
These data suggest that body composition changes
occur in most racial populations and in females as well
as males, but that the phenotype may vary considerably.
Subcutaneous fat wasting is prominent in Caucasian
males, while women and non-Caucasian races may be
more prone to develop truncal adiposity. Aside from
methodological reasons already mentioned, racial differ-
ences may also account for the widely varying
prevalence rates of ‘lipodystrophy syndrome(s)’ in
different study populations.
Risk factors and aetiopathogenesis
Though the aetiopathogenesis of lipodystrophy
syndrome(s) in HIV-infected patients is unknown,
several hypotheses, relating to retinoic acid-dependent
cell signalling, mitochondrial genomic or biochemical
toxicity, cytokine effects, immune restoration and
others, have been put forward to explain the clinical and
epidemiological observations made to date. Some of
these ideas are being tested in vitro and in vivo. There
are several key observations to be explained. NRTI
therapy alone provides sufficient conditions for develop-
ment of fat wasting and contributes independently to
risk of fat wasting in those on NRTIs plus PIs. NRTIs
have a lesser association with abdominal fat accumula-
tion and mild hypertriglyceridaemia. Conversely, PIs
alone are sufficient to induce moderate and severe
dyslipidaemia in the short term, are associated with
abdominal fat accumulation and insulin resistance, and
may have a lesser (independent) association with fat
wasting. Risk associated with agents within the NRTI
and PI classes differ. The highest prevalence, and
shortest time to onset of fat wasting is reported when PIs
and NRTIs are combined compared with the use of
either class alone. In general, different antiretroviral
drugs are associated with greater differences in risk of
lipodystrophy-related outcome measures than any
known differences in virological or immunological
effects. Thus, the emerging model of lipodystrophy
syndrome(s) is that of a collection of partially overlap-
ping PI-, NRTI-, and PI plus NRTI-associated
phenomena (Figure 2). The final expression of these
phenomena additionally depends on the age, gender,
race and other unknown genetic traits of the individual.
Management issues
Two major areas of concern to patients and clinicians
are: (i) assessment and management of dyslipidaemia
and insulin resistance, particularly in relation to its
impact on vascular risk; and (ii) halting and/or
reversing the body habitus changes. The strategies
already being used in current clinical practice are
lipid-lowering therapy, and switching antiretroviral
drugs.
M John et al.
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Figure 2. A ‘multifactorial model’ of ‘lipodystrophy syndrome(s)’ – a collection of abnormalities with partially overlapping risk
factors (PIs and NRTIs)
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There is justified concern that the cluster of lipid and
glucose abnormalities that may accompany PI therapy
constitutes an atherogenic metabolic profile. How the
baseline risk of vascular disease in HIV-infected patients
compares with the general population is not clear, nor is
whether the dyslipidaemia (and immune restoration)
induced by HAART increases this baseline risk, inde-
pendent of improved survival or improved surveillance.
There have been several case reports of premature
vascular disease in those with dyslipidaemia and/or
insulin resistance on HAART [44–53]. While early
short-term retrospective analyses in PI-treated popula-
tions did not identify an increased rate of vascular events
[112,113], a recent French study suggests that the rate of
myocardial infarction is higher among men receiving PIs
for longer than 18 months, compared with the age-
matched general population, and that there is a
dose–effect relationship [114].
An association between PI therapy and atheroscle-
rosis is suggested by studies of endothelial function and
of arterial wall morphology. Endothelial dysfunction is
considered to be an early event in atherogenesis [115],
and involves loss of the capacity of the endothelium to
respond to an ischaemic or mechanical stimulus with an
appropriate vasodilatory response. It can be assessed
non-invasively by measuring brachial artery flow-medi-
ated dilatation. A more direct indicator of
atherosclerosis may be arterial wall thickness and pres-
ence of atherosclerotic plaque in the carotid arteries.
Three recent studies of carotid wall intima media thick-
ness (IMT) [116–118] and one study of endothelial
function [119] ascribes increased risk of atherosclerotic
changes to PI use. In one study of carotid IMT, PI use
exerted the strongest influence on risk of carotid lesions
in a logistic regression analysis (OR 12.5), while ciga-
rette smoking and CD4 T cell counts of >200 cells/µl
were also predictive [118]. This dominant effect of PI
therapy per se rather than the associated dyslipidaemia
was also found in a study of endothelial function in
which a multiple linear regression model incorporating
PI therapy, systolic blood pressure and heart rate
explained 67% of the variance in endothelial function
[119]. Another study of carotid IMT in 29 dyslipidaemic
PI-treated patients found that abnormal IMT was signif-
icantly associated with age and LDL-cholesterol [117].
Notably, none of these studies demonstrated a correla-
tion between atherosclerotic changes and the typical
dyslipidaemic profile associated with PIs (increased total
cholesterol and triglycerides, and decreased HDL-
cholesterol). The association between abnormal IMT
and elevated LDL-cholesterol is also interesting, given
that this cholesterol fraction is often not significantly
affected by HAART [101].
One caveat to these findings is that changes in carotid
vessels may not necessarily correlate with increased risk
of coronary artery lesions. Two studies have assessed
coronary artery morphology directly using electron
beam-computed tomography in 85 patients, of whom
~40% had significant dyslipidaemia for approximately
24 months [120,121]. No structural changes were noted
in either study, although concurrent positron emission
tomography scanning suggested the presence of
endothelial dysfunction in the coronary vasculature.
In the absence of incidence data regarding HAART-
associated vascular disease, many physicians are
extrapolating from risk predictions in other settings and
applying (US) National Cholesterol Education Program
(NCEP) or similar consensus guidelines for lipid
lowering therapy [122–126]. Small clinical studies indi-
cate that gemfibrozil for hypertriglyceridaemia,
atorvastatin and pravastatin for hypercholesterolaemia
or mixed LDL-cholesterol and triglyceride elevations are
safe despite pharmacokinetic interaction and show
modest lipid-lowering effect [122–127]. However, it is
not yet known if lipid-lowering in the context of
HAART-treated HIV infection will result in the same
reductions in vascular events as has been documented in
the general population. The studies of endothelial func-
tion and structure in HIV-infected, PI-treated patients,
suggest that lipid levels alone may be an imperfect surro-
gate marker for true vascular risk. Indeed, even in the
general population it is not yet resolved that fasting
blood levels of cholesterol and triglyceride levels alone
are the best surrogates of atherogenesis. 
Though the use of NCEP or similar guidelines is
certainly prudent for dyslipidaemic patients, other risk
factors in all PI-treated patients need to be addressed,
including in women who may acquire the ‘android’
lipodystrophy phenotype and lose their gender-related
vascular protection [101]. Lifestyle measures to reduce
vascular risk should be actively encouraged. Resistance
exercise training in HIV-infected adults has lead to
reduction in trunk fat and hypertriglyceridaemia, as well
as improved strength and lean body mass [127,129].
Minimizing smoking, hypertension and diabetes is para-
mount, particularly in those with a family history of
premature vascular disease. In patients with pre-existing
cardiovascular disease, dyslipidaemia and/or diabetes
mellitus who are commencing antiretroviral therapy, PI-
sparing HAART regimens may merit consideration. In
centres where the expertise and technology is available,
serial assessments of vascular function and structure
performed longitudinally in PI-treated patients should
be an important research priority.
Switching antiretroviral therapy
Table 1 summarizes the results of reversibility studies
that have been presented or published to date. At the
present time, data regarding long-term risk/benefit of
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cians want to revise therapy to improve metabolic
profiles, then there is evidence that this may ensue
within a 6–12-month period if PIs are replaced with
nevirapine or abacavir [73,79–84], or if stavudine is
replaced with zidovudine or abacavir [94,95]. If the goal
of revision is to reverse established fat wasting, then
there is little evidence at the current time that a PI switch
alone will achieve this in less than 12 months. To date,
reversibility of fat wasting has only been documented
after non-randomized replacement of stavudine with
zidovudine or abacavir [95,96]. Trials in which there are
randomized changes to PIs as well as NRTIs within the
same study are currently underway. At this time of
uncertainty, enrolling patients in a reversibility trial with
objective measures of body composition change may be
the best way for physicians to switch therapy in their
patients with lipodystrophy syndrome(s).
While these studies are predicated on a potential for
reversal of body composition changes, it must be borne
in mind that the biological mechanisms of adipose loss
and gain are poorly understood at present. ‘Reversibility’
is dependent, not only on removal of the offending
drug(s), but also on the capacity for regeneration of
adipose tissue. This is, in turn, critically dependent on
whether the pathological processes involved affect
mature adipocytes but allow normal potential for
adipocyte growth and differentiation; or whether the
reservoir of adipocyte precursors and stem cells are also
targetted, leading to diminished adipose acquisition as
well as increased loss. Longitudinal data also suggests
that the process of subcutaneous fat wasting is non-
linear, following a decelerating trajectory over time [63].
If reversibility of these changes follows a similar pattern,
with small gains in fat mass first and larger incremental
gains later, revision of therapy in patients with estab-
lished severe fat wasting may require longer than 6 or 12
months for demonstrable reversibility.
Other therapies for visceral obesity and insulin resis-
tance such as metformin, PPAR-γ agonists, anabolic
steroids and recombinant human growth hormone are
being studied in small clinical trials and may have a
role for selected patients in the future. These have been
reviewed elsewhere [131].
Conclusions
The initial observations from cohort studies are being
confirmed and extended by (retrospectively designed)
cross-sectional analyses of randomized clinical trials
and reversibility studies. It is to be hoped that objective
measures of body composition (for example, whole-
body DEXA with L4 single slice CT) and metabolic
parameters (for example, fasting blood lipid profiles,
insulin resistance indices and lactate) will now be
prospectively incorporated into routine toxicity moni-
toring within randomized clinical trials. This will
additionally ensure that quality assurance issues for
such monitoring are addressed.
Perhaps the immediate priority for clinical care is to
determine which of our current HAART combinations
are least likely to lead to metabolic or morphological
change in those who are unaffected (ie ‘fat-sparing’
regimens) or will allow reversal of established changes,
while maintaining good virological control. To that
end, greater investment in randomized switching
studies is required. By necessity, assignment of ‘cases’
at a single time-point amongst antiretroviral-experi-
enced patients requires a consensus case definition.
This will be inevitably imperfect for time-dependent
outcomes and will need regular revision as new infor-
mation comes to light. Ultimately, it is likely to be
replaced by an aetiopathological definition(s). As data
obtained from clinical observational studies and clin-
ical trials continues to inform and direct in vivo and in
vitro pathogenesis studies, the mechanisms common to
apparently disparate elements of the lipodystrophy
syndrome and other complications of antiretroviral
therapy should be revealed.
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